Prof. Dr. Naomi Allen
Chief Scientist for UK Biobank and Professor of Epidemiology at the Nuffield Department of Population Health, University of Oxford | UK
With its unique combination of scale, depth, maturity and accessibility, UK Biobank is enabling researchers worldwide to perform innovative health-related research. This talk will provide key information about this landmark study, highlight recent and future enhancements to the resource, and new ways in which it is democratising access via the new cloud-based Research Analysis Platform.
UK Biobank is a prospective cohort study of 500,000 people that has integrated large-scale genomic data (in all participants) and deep phenotyping data (including lifestyle factors, physical measures and multi-modal imaging) with long-term follow-up of health outcomes through linkage to electronic health records. The recent addition of detailed genomic sequencing data plus large-scale metabolomic and proteomic data has created an even more powerful resource, which will enable a better understanding of disease biology and will support innovative drug development for more effective therapies. To accommodate the rapid growth of the resource and to enable more researchers across the world to access these data without limitations of transferring, collating, storing, and accessing data at this scale, UK Biobank has launched an cloud-based Research Analysis Platform, democratising access to large-scale compute and novel technologies. The availability of financial research credits for early-career researchers and those from low-income and middle-income countries is further democratising access to this unique resource.
Ready access to the combination of in-depth genomic, imaging, and other health information from 500,000 UK Biobank participants is enabling researchers worldwide to advance discovery science and improve human health.
[ Ссылка ]
